Annual D&A:
$36.49M+$12.09M(+49.55%)Summary
- As of today, RXRX annual D&A is $36.49 million, with the most recent change of +$12.09 million (+49.55%) on December 31, 2024.
- During the last 3 years, RXRX annual D&A has risen by +$28.09 million (+334.19%).
- RXRX annual D&A is now at all-time high.
Performance
RXRX Depreciation & Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly D&A:
$23.85M+$4.52M(+23.37%)Summary
- As of today, RXRX quarterly D&A is $23.85 million, with the most recent change of +$4.52 million (+23.37%) on June 30, 2025.
- Over the past year, RXRX quarterly D&A has increased by +$14.88 million (+165.93%).
- RXRX quarterly D&A is now at all-time high.
Performance
RXRX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM D&A:
$63.33M+$14.88M(+30.72%)Summary
- As of today, RXRX TTM D&A is $63.33 million, with the most recent change of +$14.88 million (+30.72%) on June 30, 2025.
- Over the past year, RXRX TTM D&A has increased by +$31.85 million (+101.20%).
- RXRX TTM D&A is now at all-time high.
Performance
RXRX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
RXRX Depreciation & Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +49.5% | +165.9% | +101.2% |
| 3Y3 Years | +334.2% | +756.0% | +519.4% |
| 5Y5 Years | +1366.2% | +2229.0% | +2147.3% |
RXRX Depreciation & Amortization Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +334.2% | at high | +697.9% | at high | +487.6% |
| 5Y | 5-Year | at high | +1366.2% | at high | +2682.8% | at high | +2147.3% |
| All-Time | All-Time | at high | +1366.2% | at high | +2682.8% | at high | +6658.7% |
RXRX Depreciation & Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $23.85M(+23.4%) | $63.33M(+30.7%) |
| Mar 2025 | - | $19.33M(+49.3%) | $48.45M(+32.8%) |
| Dec 2024 | $36.49M(+49.6%) | $12.95M(+79.9%) | $36.49M(+17.4%) |
| Sep 2024 | - | $7.20M(-19.7%) | $31.10M(-1.2%) |
| Jun 2024 | - | $8.97M(+21.6%) | $31.48M(+12.2%) |
| Mar 2024 | - | $7.38M(-2.3%) | $28.05M(+15.0%) |
| Dec 2023 | $24.40M(+107.6%) | $7.55M(-0.3%) | $24.40M(+21.6%) |
| Sep 2023 | - | $7.58M(+36.7%) | $20.06M(+29.7%) |
| Jun 2023 | - | $5.54M(+48.7%) | $15.47M(+21.7%) |
| Mar 2023 | - | $3.73M(+16.0%) | $12.72M(+8.2%) |
| Dec 2022 | $11.76M | $3.21M(+7.5%) | $11.76M(+9.1%) |
| Sep 2022 | - | $2.99M(+7.3%) | $10.78M(+5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | $2.79M(+0.7%) | $10.22M(+4.7%) |
| Mar 2022 | - | $2.77M(+23.7%) | $9.77M(+16.2%) |
| Dec 2021 | $8.40M(+113.2%) | $2.24M(-8.2%) | $8.40M(+15.2%) |
| Sep 2021 | - | $2.44M(+4.5%) | $7.29M(+27.6%) |
| Jun 2021 | - | $2.33M(+66.3%) | $5.71M(+29.7%) |
| Mar 2021 | - | $1.40M(+24.6%) | $4.41M(+11.8%) |
| Dec 2020 | $3.94M(+58.4%) | - | - |
| Dec 2020 | - | $1.13M(+31.3%) | $3.94M(+39.9%) |
| Sep 2020 | - | $857.00K(-16.3%) | $2.82M(+43.7%) |
| Jun 2020 | - | $1.02M(+9.3%) | $1.96M(+109.3%) |
| Mar 2020 | - | $937.00K | $937.00K |
| Dec 2019 | $2.49M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual D&A?
- What is the all-time high annual D&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual D&A year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly D&A?
- What is the all-time high quarterly D&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly D&A year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM D&A?
- What is the all-time high TTM D&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM D&A year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual D&A?
The current annual D&A of RXRX is $36.49M
What is the all-time high annual D&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual D&A is $36.49M
What is Recursion Pharmaceuticals, Inc. annual D&A year-on-year change?
Over the past year, RXRX annual D&A has changed by +$12.09M (+49.55%)
What is Recursion Pharmaceuticals, Inc. quarterly D&A?
The current quarterly D&A of RXRX is $23.85M
What is the all-time high quarterly D&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly D&A is $23.85M
What is Recursion Pharmaceuticals, Inc. quarterly D&A year-on-year change?
Over the past year, RXRX quarterly D&A has changed by +$14.88M (+165.93%)
What is Recursion Pharmaceuticals, Inc. TTM D&A?
The current TTM D&A of RXRX is $63.33M
What is the all-time high TTM D&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM D&A is $63.33M
What is Recursion Pharmaceuticals, Inc. TTM D&A year-on-year change?
Over the past year, RXRX TTM D&A has changed by +$31.85M (+101.20%)